Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Visx Cuts To The Chase, Files Patent Complaint Against Nidek At ITC

This article was originally published in The Gray Sheet

Executive Summary

Nidek's importation and sale of the EC5000 excimer laser is currently under investigation by the U.S. International Trade Commission to determine whether doing so infringes three VISX laser system patents, VISX announced Feb. 25.

You may also be interested in...

Visx v. Nidek ITC LASIK Ruling May Open Door For Bausch & Lomb, Others

A recent ruling by the International Trade Commission weakens, at least temporarily, the patent position of Visx and co-licensor Summit Technology in the rapidly growing laser-assisted in situ keratomileusis (LASIK) market, and creates an opening for a formidable competitor, Bausch & Lomb, whose Technolas LASIK device awaits FDA approval.

At Muted J.P. Morgan, Focus Is Execution, But US Pricing Is Persistent Overhang

Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts